// App-Quantinova.ai

: PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).

Researchers

Presenter

  • Kim N. Chi

Principal Investigators

  • Mark T. Fleming

  • Katherine Sunderland

  • Costantine Albany

  • Joel Gingerich

  • Fred Saad

  • Scott A. North

  • Alexander Starodub

  • Richard C. Lauer

  • Joseph D. Ruether

  • Madelaine Miranda Sgroi

  • Mark C. Scholz

  • Christopher Sweeney

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • US Oncology Research, Virginia Oncology Associates, Hampton, VA

  • BC Cancer Agency, Vancouver, BC, Canada

  • Indiana University School of Medicine, Indianapolis, IN

  • Cancer Care Manitoba, Winnipeg, MB, Canada

  • University of Montreal, Montreal, QC, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Indiana University Health Center for Cancer Care, Goshen, IN

  • University of New Mexico Cancer Center, Albuquerque, NM

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Central Indiana Cancer Center, Indianapolis, IN

  • Prostate Oncology Specialists, Marina del Rey, CA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Apoptotic body index

Drug/Treatment

  • CB-7598

  • Prednisone

  • Apatorsen

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • NA

Study Id's

  • NCT01681433

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved